UnitedHealthcare Starting Coverage of Veractye's Thyroid Cancer MDx | GenomeWeb

NEW YORK (GenomeWeb News) – Veracyte today announced that private payor UnitedHealthcare has issued a positive medical coverage policy for the firm's molecular diagnostic test for thyroid cancer.

The decision by UHC, which covers about 27 million commercial members, pertains to Veracyte's Afirma Gene Expression Classifier for assessing thyroid nodule fine needle aspirate biopsies that are neither clearly benign nor malignant based on cytology review. The policy takes effect April 1.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."